key takeaway hq visit bd core revenu growth target
upward bia dd ep growth reason even headwind bard synergi
target achiev bard/new hire improv talent bd
capit structur allow flexibl strateg point emphasi note
sell side estim look high
manag remain comfort annual core revenu growth target
believ revenu synergi bard carefus posit bd hit
higher end target could allow upsid
time bard deal manag guid street expect doubl digit ep
growth next sever year target remain intact true even
headwind couldnt expect time target set resin
bd great job walk us methodolog compani
target revenu cost synergi deriv left
meet increment confid achiev target better
understand cost synergi target yet increas still could
impress bd level integr adopt carefus bard
leadership team best practic new senior hire also help manag
note bard expand deepen leadership capabl across number
function numer exampl provid includ area prioritization/
manag synergi manag
bd continu target sustain dividend get sens return
polici deploy share repurchas possibl compani
de-lev expect time said focu like
limit tuck-in variat valu debt/ebitda get
bigger deal strategy-depend view good
consolid necessarili consolid
talk expect recal compani guid quarterli
expect said becam clear us sell side expect high
base observ share meet dynam fx
tough flu comparison order time dynam normal quarterli pace cours
year made adjust forecast importantli pleas note
fy estim chang
pleas see page report import disclosur
appear well posit gener sustain msd top line ep growth
upsid oper target via on-going stand-alone improv carefus
upsid rel formal accretion/
price pressur like continu
volum pressur like intensifi
solid execut rel expect
carefusion/bard synergi accret
target conserv
strong growth emerg market
bd guidanc prove high
bard miss accret synergi
concern strategi
becton dickinson compani bd global medic technolog compani engag
develop manufactur sale medic devic instrument system
reagent use healthcar institut life scienc research clinic laboratori
pharmaceut industri gener public
manag note annual revenu growth target outlin time
bard deal believ revenu synergi posit bd hit
higher end target see detail
oper margin expans guid recal bd origin bd-
bard deal model target margin expans averag
believ underli margin expans still track hit origin target
adjust item includ fx tariff raw materi cost
manag continu believ annual ep growth
possibl despit increment headwind embed origin guidanc
remind bd guid bard revenu synergi manag
develop target meticul systemat bottoms-up build
relev busi region provid detail plan gener revenu synergi
accordingli manag sound highli confid achiev revenu synergi
revenu synergi expect contribut revenu growth
ramp beyond three primari sourc revenu
forc leverag bd infrastructur emerg market latin america
asia ex-china broader vascular access product portfolio expect gener
half total revenu synergi target remain bucket
contribut half least believ revenu synergi allow
bd hit higher end annual revenu growth target per annum
synergi expect approxim expect driven
elimin duplic public compani cost harmonizing/integr variou
system hr variou infrastructur manufacturing/factori
consolid respons question similar amount
upsid initi cost synergi target bard carefus cfn cost
synergi target increas within year deal
close manag assert bard cost synergi appropri
calcul given compani experi reduc public compani cost
addit get sens bd still earli stage implement
manufactur cost synergi would prematur rais cost synergi guidanc
current junctur
bd acquisit carefus bard serv broaden compani product
portfolio improv valu proposit custom manag assert
bd better posit strateg partner custom given import
preval bd product within hospit organ bd radar
essenti hospit manag expect benefit hospit merger trend
custom seek consolid vendor base lower cost price like
modest headwind product manag assert would like
off-set suppli broader suit product price off-set
bd better posit one select number diversifi med-tech vendor
engag strateg partner/sel hospit c-suit sinc carefus
acquisit strateg point focu bd past year bard
acceler strategi product portfolio deliv deep clinic valu
best practic bd leverag
part strategi bd also pilot key account model strategi strategi
compani success employ specif involv
establish global account manag structur instead individu rep work
close key account across qualiti suppli exampl pharm
system manag note strategi dramat strengthen bd
relationship custom competit corpor contract expect
strategi allow bd gain share increas custom sticki
impress bd level integr adopt carefus bard
leadership team best practic manag note bard expand
deepen leadership capabl across number function specif exampl
provid includ bring head human resourc chief counsel key
account manag team bard addit bd appoint well-respect
talent veteran bard leader john deford role chief technolog offic
manag particularli enthus potenti optim
enhanc productivity/innov beyond leadership gain bard
manag also highlight hire patrick kaltenbach veteran agil
employe lead bd life scienc
exampl best practic adopt bard includ monthli oper review
process process expect drive better align increas account
across busi addit process afford bd flexibl implement
remedi plan necessari ultim believ practic better
posit bd meet/exce financi target
high profil project ultim
scrapped/sold past sever year manag note vast major
project success addit manag work minim
failur note compani like wouldnt take enough risk new
product develop limit line extens
addit new see expect enhanc product
innov encouragingli manag note bard prudent
disclos project earli believ practic bd like adopt
bd note compani develop numer capabl part acquisit
integr carefus bard context reduc organiz complex
build platform effici integr busi importantli
capabl better posit bd futur especi medium-to-larg scale
acquisit said manag clear compani strategi
serial acquir add capabl made strateg sens
increas valu deliv custom
bd philosophi driven strategi size current focus tuck-in
deal compani de-lev debt/ebitda debt pay
manag assert compani clearli capabl cash flow
complet anoth larg acquisit though reiter focu
strategi size
bd current target low dividend pay-out ratio estim
sustain dividend rate given current cash flow growth profil
ask manag share buyback believ option
bd explor suffici de-lev prior acquisit carefus
bard annual util share purchas
manag provid quarterli guidanc remind investor
numer discret item expect impact result
includ difficult flu comparison flu contribut increment
growth includ
medic manag revenu pull forward primarili
fx headwind acut impact result
result factor get sens manag comfort
ep growth lsd impli better reflect aforement
headwind updat revenu estim
current consensu rang ep
estim current consensu rang
importantli full year revenu ep estim remain larg unchang
cost headwind associ us-china trade tariff expect approxim
howev guidanc assum net impact
manag work supplier implement initi help off-set
increment cost key initi pass tariff cost via price though
manag note alreadi larg embed guidanc
temporari trade truce expect repres coupl million dollar benefit
rel origin guidanc would greater benefit higher tariff rate
implement
oil price move meaning lower expect materi
benefit resin price remind resin price increas primarili due suppli
constraint increas oil price earlier calendar year manag
note suppli constraint eas benefit expect
approxim million dollar rel origin guidanc translat
basi point cog line rel immateri figur
gore royalti track manag origin deal expect gore royalti
expect approxim annual gore royalti expect
roll-off end balanc come
importantli manag remain confid abl deliv least
annual ep growth spite gore royalti headwind interest
reduct key off-set
manag done remark job lower bd tax rate
sinc acquisit carefus bard manag believ tax rate
sustain could littl room tax optim
effort lower tax rate would like face diminish return
manag clearli enthus lutonix below-the-kne btk data
releas novemb note data also well receiv
medic commun manag continu believ btk indic repres
market opportun fda pma approv expect end
advisori panel review requir approv possibl acceler
review importantli guidanc assum panel review accordingli acceler
review could drive revenu upsid
compani report thomson eikon cowen compani
fy end septemb end septemb end septemb year mm except report growth compar fxn growthreport growth expect back end loadedfx neutral fx headwind forma bd-bard report growth compar fxn growth forma compar growth expect back end load forma fx fx adjust neutral forma compar forma revenu segment fxn forma compar intervent reiter expect higher end rangefx neutral fxn forma compar life neutral organ fxn cowen
compani report thomson eikon cowen compani
mm except per share report growth compar fxn growth expect back end loadedconst fx headwind organ sale gener sale oper fxn non-oper interest interest/oth note estim gore headwind convert share may earn per fxn report hsd bard accretionshar except per share gross op cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
downsid risk includ limit inabl execut integr
approv reduc reimburs patent infring product liabil lawsuit
macroeconom deterior current level eros market share price due
competit inabl deliv incremental/decrement margin target value-
